Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized p...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BMC cancer Ročník 19; číslo 1; s. 816 - 15
Hlavní autori:	Palma, David A., Olson, Robert, Harrow, Stephen, Correa, Rohann J. M., Schneiders, Famke, Haasbeek, Cornelis J. A., Rodrigues, George B., Lock, Michael, Yaremko, Brian P., Bauman, Glenn S., Ahmad, Belal, Schellenberg, Devin, Liu, Mitchell, Gaede, Stewart, Laba, Joanna, Mulroy, Liam, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Warner, Andrew, Slotman, Ben J., de Gruijl, Tanja D., Allan, Alison, Senan, Suresh
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 19.08.2019 BioMed Central Ltd BMC
Predmet:	Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Cancer Cancer metastasis Cancer Research Care and treatment Clinical trials DNA Dose Fractionation, Radiation Female Follow-Up Studies Health Promotion and Disease Prevention Humans Magnetic Resonance Imaging Male Medical and radiation oncology Medical research Medicine/Public Health Neoplasms - blood Neoplasms - diagnostic imaging Neoplasms - radiotherapy Neoplastic Cells, Circulating - radiation effects Oligometastases Oncology Patient outcomes Patient Selection Prognosis Progression-Free Survival Quality of Life Radiosurgery Radiotherapy Retirement benefits Stereotactic radiotherapy Study Protocol Surgical Oncology Surveys and Questionnaires Survival Tomography, X-Ray Computed Toxicity Tumor Burden Tumors Canada Oligometastases Survival Stereotactic radiotherapy Quality of life Cancer
ISSN:	1471-2407, 1471-2407
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!